Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioXXmed AGHAM:T5O 33 PS Ratio is 12.22 as of Jul. 16, 2026, which is 95% below its 10-year median of 268.02. GuruFocus rates HAM:T5O with a GF Score™ of 33/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, bioXXmed AG ranks worse than 55.27% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, bioXXmed AG's share price is €0.77.
bioXXmed AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06. Hence, bioXXmed AG's PS Ratio for today is 12.22.
The historical rank and industry rank for bioXXmed AG's PS Ratio or its related term are showing as below:
HAM:T5O'
s PS Ratio Range Over the Past 10 Years
Min: 3.97 Med: 268.02 Max: 39429.24
Current: 12.22
During the past 13 years, bioXXmed AG's highest PS Ratio was 39429.24. The lowest was 3.97. And the median was 268.02.
HAM:T5O's PS Ratio is ranked worse than 55.27% of 930
companies
in the Biotechnology industry
Industry Median: 9.655
vs HAM:T5O: 12.22
bioXXmed AG revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of bioXXmed AG was 472.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -43.90% per year.
During the past 13 years, bioXXmed AG's highest 3-Year average Revenue per Share Growth Rate was 213.90% per year. The lowest was -71.90% per year. And the median was -28.00% per year.
Back to Basics: PS Ratio
bioXXmed AG (HAM:T5O) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
bioXXmed AG PS Ratio Related Terms
bioXXmed AG PS Ratio Historical Data
* Premium members only.
The historical data trend for bioXXmed AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, bioXXmed AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioXXmed AG PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, bioXXmed AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where bioXXmed AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
bioXXmed AG's Share Price of today is €0.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. bioXXmed AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
bioXXmed AG (HAM:T5O) has a PS Ratio of 12.22 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on bioXXmed AG and its competitors. This is 95% below median its historical median of 268.02. Over the past decade, bioXXmed AG's PS Ratio has ranged from 3.97 to 39,429.24. According to the industry distribution chart, bioXXmed AG ranks #514 out of 930 companies in the Biotechnology industry, placing it in the top 55.3%.
Is bioXXmed AG's PS Ratio too high?
bioXXmed AG's current PS Ratio of 12.22 is 95% below median its 10-year median of 268.02. Over the past 10 years, this metric has ranged from a low of 3.97 to a high of 39,429.24. The Biotechnology industry median PS Ratio is 9.66. bioXXmed AG's value of 12.22 is 26.6% above this industry median. Based on the distribution chart, bioXXmed AG ranks #514 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, bioXXmed AG has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, bioXXmed AG ranks #514 out of 930 companies for PS Ratio. This places bioXXmed AG in the lower half of its industry. The industry median PS Ratio is 9.66. bioXXmed AG's value of 12.22 is 26.6% above this benchmark. Historically, bioXXmed AG's own PS Ratio has ranged from 3.97 to 39,429.24 over the past decade. While the company's 10-year median is 268.02 vs. the industry median of 9.66, bioXXmed AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioXXmed AG's current PS Ratio of 12.22 is 26.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on bioXXmed AG and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioXXmed AG's current PS Ratio is 12.22, which is 95% below median its own 10-year median of 268.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current PS Ratio is 12.22, which is 95% below median its 10-year median of 268.02 and 26.6% above the Biotechnology industry median of 9.66. bioXXmed AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current PS Ratio is 12.22 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioXXmed AG (HAM:T5O) Overvalued in 2026?
Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued.
The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07.
GuruFocus considers bioXXmed AG to be Possible Value Trap.
Key valuation signals for HAM:T5O:
PS Ratio: 12.22 (95% below median its 10-year median of 268.02)
GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
Industry Position: 26.6% above the Biotechnology median (#514 of 930)
No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
33GF Score
Get the complete analysis for HAM:T5O
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:T5O has been successfully added to your 
